Citigroup has upgraded Thermo Fisher Scientific Inc (TMO) to a Buy rating from Neutral, effective December 10, 2025. The new rating comes as the company’s stock is priced at $574.90.
This upgrade reflects a more optimistic outlook on Thermo Fisher's prospects, potentially indicating improved fundamentals or heightened confidence in the company's strategic direction. The life sciences tools and services provider serves the scientific community with a broad range of innovative products and services, and currently boasts a market capitalization of $212.6 billion.
Thermo Fisher's financial metrics reveal a P/E ratio of 32.38 and an EPS of 17.30, with a substantial dividend yield of 30.3%. The company is set to report its upcoming earnings on July 21, 2026, with estimates of $5.94 per share on revenue of $11.6 billion.
Analyst consensus as of December 1, 2025, shows 8 Strong Buy, 17 Buy, and 6 Hold ratings among 31 total analysts, suggesting a generally favorable view of the company's future performance. Recent analyst actions have included upgrades from Goldman Sachs and HSBC, underscoring a positive shift in sentiment across the board.
While analyst ratings can provide valuable insights, they should be considered alongside other factors such as company fundamentals, competitive positioning, and individual financial goals. Analyst opinions may evolve as new information becomes available, reflecting the dynamic nature of market assessments.